Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Lipomedix Pharmaceuticals Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
22Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04729205CT.gov Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intraepithelial Neoplasia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Promitil (this asset) | Lipomedix Pharmaceuticals Inc. | P1 | C · 37 |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| 9-valent human papillomavirus recombinant vaccine | Xiamen University | P3 | B |
| Abi-1968 | Antiva Biosciences | P1 | NR |
Other indications for Promitil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P2 | CC · 43 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | CC · 42 |
| Colorectal Cancer | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Promitil in Intraepithelial Neoplasia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/promitil-intraepithelial-neoplasia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →